Androgenic Alopecia TH07 Clinical Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: TH07, TH07, Minoxidil 5% Topical Solution, Placebo.
- Who it may be relevant to
- Registry conditions: Androgenic Alopecia. Basic parameters: 18 years — 49 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.
Overview
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
Detailed description
The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.
TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.
Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.
The treatment will be applied daily (once or twice) for 24 weeks.
Interventions
- Drug TH07
TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day - Drug TH07
* TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day - Drug Minoxidil 5% Topical Solution
Minoxidil 5%; topical solution; twice a day - Other Placebo
Placebo; topical solution; twice a day
Primary outcome measures
- Non-vellus hair count [Time frame: Baseline and week 24]
Secondary outcome measures (4)
- Hair diameter and cumulative hair thickness [Time frame: Baseline and week 24]
- Subject-reported improvement [Time frame: week 24]
- Non-vellus hair count [Time frame: Baseline and week 24]
- Incidence of treatment related adverse events. [Time frame: through study completion, average 28 weeks]
Eligibility criteria
Inclusion criteria
- Males, 18 to 49 years of age on the date of enrollment.
- Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
- Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
- Not administered any systemic or topical treatment for AGA during the last 90 days.
- Willing to comply with the following restrictions for the duration of trial participation:
- Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
- Hair dyes, hair texturizers, relaxers etc.
- Any new vitamins or nutritional supplements that are currently not being administered.
- Tattooing in the trial target area.
- Blood donations.
- OTC hair restorers.
- Do not expose your pregnant partner to your hands/skin where the drug might be present.
- Participation in any other drug or device trials during the course of this trial.
Note: However, the following shall be permissible:
- Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
- Current regimen (if any) of vitamins and nutritional supplements.
- Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements.
- Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.
Exclusion criteria
- History of scalp treatment including though not limited to any of the following:
- Hair transplant or extension surgery.
- Hair weaving.
- Laser or light therapy on the scalp in the last 6 months.
- Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.
5-Any other surgical treatment for hair loss
- Any of the following hair styles:
1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
- Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
- Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
- History or likelihood of use of any of the specified medicines.
- History or clinical diagnosis of any of the specified medical conditions.
- Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial.
- Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Canada · 1 center
- YVR Aesthetic Training and Study Centre. — Vancouver
Identifiers
NCT: NCT07435012 · TH0701